Recombinant Human Kallikrein 2/KLK2 Protein (His Tag)

Catalog Number: PKSH032666



Note: Centrifuge before opening to ensure complete recovery of vial contents.

-					
- 10	00	cri	m	17	٦m
u		\mathbf{u}		7 U	

 Species
 Human

 Mol_Mass
 27.9 kDa

 Accession
 P20151

Bio-activity Not validated for activity

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin < 0.01 EU per μ g of the protein as determined by the LAL method. **Storage** Store at $< -20^{\circ}$ C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel


packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as a 0.2 μm filtered solution of 20mM Acetate, 250mM Trehalose, 0.02%

Tween 80, pH5.0.

Reconstitution Not Applicable

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Me t-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer.

For Research Use Only